These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11923638)

  • 21. First in vivo MRI assessment of a self-assembled metallostar compound endowed with a remarkable high field relaxivity.
    Livramento JB; Weidensteiner C; Prata MI; Allegrini PR; Geraldes CF; Helm L; Kneuer R; Merbach AE; Santos AC; Schmidt P; Tóth E
    Contrast Media Mol Imaging; 2006; 1(1):30-9. PubMed ID: 17193598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol).
    Bradley DP; Tessier JL; Checkley D; Kuribayashi H; Waterton JC; Kendrew J; Wedge SR
    NMR Biomed; 2008 Jan; 21(1):42-52. PubMed ID: 17458919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimization of a blood pool contrast agent injection protocol for MR angiography.
    Robert P; Violas X; Santus R; Le Bihan D; Corot C
    J Magn Reson Imaging; 2005 May; 21(5):611-9. PubMed ID: 15834909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Nephrotoxicity of contrast media in magnetic resonance tomography (MRI)].
    Heuck A; Reiser M
    Internist (Berl); 1997 Dec; 38(12):1234-5. PubMed ID: 9465330
    [No Abstract]   [Full Text] [Related]  

  • 25. Safety of magnetic resonance imaging contrast agents.
    Shellock FG; Kanal E
    J Magn Reson Imaging; 1999 Sep; 10(3):477-84. PubMed ID: 10508312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contrast-enhanced magnetic resonance angiography: P792 blood pool agent versus Gd-DOTA in rabbits at 3.0 T versus 1.5 T.
    Herborn CU; Watkins DM; Baumann S; Robert P; Corot C; Runge VM
    Invest Radiol; 2007 Sep; 42(9):622-8. PubMed ID: 17700277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dy-EOB-DTPA: tolerance and pharmacokinetics in healthy volunteers and preliminary liver imaging in patients.
    Krause W; Mahler M; Hanke B; Milius W; Kaufmann J; Rogalla P; Hamm B
    Invest Radiol; 2001 Aug; 36(8):431-44. PubMed ID: 11500593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and safety of the MRI contrast agent gadoversetamide injection (OptiMARK) in healthy pediatric subjects.
    Baker JF; Kratz LC; Stevens GR; Wible JH
    Invest Radiol; 2004 Jun; 39(6):334-9. PubMed ID: 15167099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and safety of gadobenate dimeglumine (multihance) in subjects with impaired liver function.
    Davies BE; Kirchin MA; Bensel K; Lorusso V; Davies A; Parker JR; Lafrance ND
    Invest Radiol; 2002 May; 37(5):299-308. PubMed ID: 11979156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of myocardial infarction in pigs using a rapid clearance blood pool contrast medium.
    Dewey M; Kaufels N; Laule M; Schnorr J; Wagner S; Kivelitz D; Raynaud JS; Robert P; Hamm B; Taupitz M
    Magn Reson Med; 2004 Apr; 51(4):703-9. PubMed ID: 15065242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Revisiting the Pharmacokinetic Profiles of Gadolinium-Based Contrast Agents: Differences in Long-Term Biodistribution and Excretion.
    Lancelot E
    Invest Radiol; 2016 Nov; 51(11):691-700. PubMed ID: 27175546
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brain tumor enhancement in magnetic resonance imaging at 3 tesla: intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular gd-chelate in a rat brain tumor model.
    Fries P; Runge VM; Bücker A; Schürholz H; Reith W; Robert P; Jackson C; Lanz T; Schneider G
    Invest Radiol; 2009 Apr; 44(4):200-6. PubMed ID: 19300099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel gadolinium-based trimetasphere metallofullerene for application as a magnetic resonance imaging contrast agent.
    Adiseshaiah P; Dellinger A; MacFarland D; Stern S; Dobrovolskaia M; Ileva L; Patri AK; Bernardo M; Brooks DB; Zhou Z; McNeil S; Kepley C
    Invest Radiol; 2013 Nov; 48(11):745-54. PubMed ID: 23748228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end-stage renal disease requiring hemodialysis.
    Lorusso V; Taroni P; Alvino S; Spinazzi A
    Invest Radiol; 2001 Jun; 36(6):309-16. PubMed ID: 11410750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and safety of gadobutrol-enhanced magnetic resonance imaging in pediatric patients.
    Hahn G; Sorge I; Gruhn B; Glutig K; Hirsch W; Bhargava R; Furtner J; Born M; Schröder C; Ahlström H; Kaiser S; Moritz JD; Kunze CW; Shroff M; Stokland E; Trnkova ZJ; Schultze-Mosgau M; Reif S; Bacher-Stier C; Mentzel HJ
    Invest Radiol; 2009 Dec; 44(12):776-83. PubMed ID: 19858730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical evaluation of the pharmacokinetics, biodistribution, and elimination of MS-325, a blood pool agent for magnetic resonance imaging.
    Parmelee DJ; Walovitch RC; Ouellet HS; Lauffer RB
    Invest Radiol; 1997 Dec; 32(12):741-7. PubMed ID: 9406014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
    Lohrke J; Frisk AL; Frenzel T; Schöckel L; Rosenbruch M; Jost G; Lenhard DC; Sieber MA; Nischwitz V; Küppers A; Pietsch H
    Invest Radiol; 2017 Jun; 52(6):324-333. PubMed ID: 28323657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cerebral MR perfusion imaging: first clinical application of a 1 M gadolinium chelate (Gadovist 1.0) in a double-blinded randomized dose-finding study.
    Benner T; Reimer P; Erb G; Schuierer G; Heiland S; Fischer C; Geens V; Sartor K; Forsting M
    J Magn Reson Imaging; 2000 Sep; 12(3):371-80. PubMed ID: 10992303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gd-DOTA. Pharmacokinetics and tolerability after intravenous injection into healthy volunteers.
    Le Mignon MM; Chambon C; Warrington S; Davies R; Bonnemain B
    Invest Radiol; 1990 Aug; 25(8):933-7. PubMed ID: 2394577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monitoring blood-brain barrier status in a rat model of glioma receiving therapy: dual injection of low-molecular-weight and macromolecular MR contrast media.
    Lemasson B; Serduc R; Maisin C; Bouchet A; Coquery N; Robert P; Le Duc G; Troprès I; Rémy C; Barbier EL
    Radiology; 2010 Nov; 257(2):342-52. PubMed ID: 20829544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.